Relay Therapeutics, Inc.
Relay Therapeutics, Inc. is a U.S.-based clinical-stage precision medicine company focused on discovering and developing small-molecule therapies for cancer and genetic diseases. The company’s work centers on its Dynamo platform, which combines computational and experimental methods to design drugs against protein targets that have been difficult to address with traditional approaches.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueSmall-molecule therapeutic candidates in clinical development, including the lead oncology program.
Discovery-stage programs in precision oncology and genetic diseases before first-in-human testing.
Computational and experimental capabilities used to identify and optimize new drug candidates.
Revenue from research collaborations, licenses, and related contractual arrangements.
Customers
Relay Therapeutics does not currently sell approved products to end patients; its economic counterparties are primarily collaboration partners and licensees. If its candidates are commercialized, the ultimate users would be physicians, healthcare providers, and third-party payors that influence prescribing and reimbursement in oncology and rare disease settings.
Companies that license programs or collaborate on discovery and development to access Relay's platform and assets.
Smaller drug developers that may co-develop or license programs for specific targets or indications.
Potential prescribers of approved therapies, especially specialists in oncology and genetic disease.
Insurers and reimbursement bodies that would influence access and uptake after approval.
Patients identified by molecular diagnostics for targeted treatment in oncology or genetic disease.
Strategy
Relay Therapeutics is focused on advancing a platform-led pipeline in precision oncology and genetic disease, using computational and experimental tools to improve target selection and molecule design. Its strategy is to move product candidates from discovery into clinical development and, where useful, through collaborations or licenses that support development and future commercialization.
Clinical proof-of-concept is the key value driver for a biotech with no marketed products.
Multiple shots on goal reduce dependence on any single asset or indication.
Platform productivity supports repeatable discovery and differentiation versus single-asset peers.
Collaborations can provide validation, resources, and development support.
Geography
Relay Therapeutics is headquartered in Cambridge, Massachusetts and conducts research and development primarily from the United States. Its business also depends on foreign contract manufacturing organizations and other third parties, which creates operational exposure outside the U.S. even though the company is not yet commercializing products.
Risks
Relay Therapeutics faces the typical risks of a clinical-stage biotech: trial failure, regulatory delays, and uncertainty around whether product candidates will ever reach approval. Its dependence on third-party manufacturers, collaborators, and external supply chains adds execution risk, while future commercialization would also introduce reimbursement, market access, and healthcare compliance risk.
- Failure in pivotal clinical developmentImpact: HighLikelihood: Medium
The company has not yet successfully completed large-scale pivotal trials, so late-stage attrition remains a major risk.
Exposure: Lead and pipeline candidates
- Regulatory approval riskImpact: HighLikelihood: Medium
Even promising data may not translate into approval if regulators require additional evidence or identify safety issues.
Exposure: All product candidates
- Third-party manufacturing and supply chain dependenceImpact: HighLikelihood: Medium
The company relies on foreign CMOs and external suppliers for investigational materials and APIs.
Exposure: Clinical and preclinical supply
- Collaboration and licensing execution riskImpact: MediumLikelihood: Medium
Milestones, reimbursements, and development support depend on counterparties and contract terms.
Exposure - Future commercialization and reimbursement riskImpact: MediumLikelihood: Medium
If approved, uptake will depend on physician adoption and third-party payor coverage.
Exposure: Potential marketed products
Accounting
Judgemental itemsLicense and other revenue is recognized under contract terms and performance obligations, affecting timing and comparability.
Impact: Genentech and Elevar-related revenue
CRO and site costs are recognized based on progress estimates rather than invoice timing.
Impact: R&D expense volatility
Payments for development activities may not match the period in which services are performed.
Impact: Quarterly operating expense timing
Office and laboratory leases affect right-of-use assets, liabilities, and occupancy expense.
Impact: G&A and facility cost presentation
Valuation judgments can affect contingent liabilities or acquired in-process R&D balances.
Impact: Non-cash gains/losses and balance sheet estimates
Similar listed companies
Publicly listed companies with a comparable business focus.
Tango Therapeutics, Inc.
TNGX · Pharmaceutical Preparations
Maze Therapeutics, Inc.
MAZE · Biological Products, (No Diagnostic Substances)
Cero Therapeutics Holdings, Inc.
CEROW · Biological Products, (No Diagnostic Substances)
Compass Therapeutics, Inc.
CMPX · Biological Products, (No Diagnostic Substances)
Compass Therapeutics is a clinical-stage biopharmaceutical company focused on developing antibody-based cancer therapies.
Xilio Therapeutics, Inc.
XLO · Pharmaceutical Preparations
Xilio Therapeutics is a U.S.-based biotechnology company focused on developing tumor-activated immunotherapies for cancer.
ZyVersa Therapeutics, Inc.
ZVSA · Pharmaceutical Preparations
Last updated: 24/09/2026